Fresenius completa la adquisición de mAbxience, creando una plataforma más sólida para la futura expansión de su cartera de productos
/PRNewswire/ -- mAbxience ha anunciado hoy que Fresenius SE & Co. KGaA ha adquirido el 45% restante de mAbxience a Insud Pharma, consolidando así la exitosa...
Short extract only — this publisher licenses its text. Read the full release at the source.
More from Commercial newswire
- Piramal Pharma Solutions y NP2 completan la fase de desarrollo de ciclofosfamida el próximo mes
- Estudio de Nielsen IQ a consumidores europeos
- Newronika anuncia el primer participante implantado en el estudio pivotal ADVENT
The rest of this wire is for subscribers
Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
7 days, no card required.
Read releases like this the second they cross the wire.
1,400+ feeds — live on PPN World right now. Every release from this source, the moment it crosses — plus 80+ other newswires, saved searches and instant alerts.
Start the free trial →Your announcement next? Distribute your press release to the global wires with PPN Source — and track its pickup live here.
PPN Source →